These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39060084)

  • 21. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort.
    Makino T; Nakai S; Momose K; Yamashita K; Tanaka K; Miyata H; Yamamoto S; Motoori M; Kimura Y; Ushimaru Y; Hirao M; Matsuyama J; Akamaru Y; Kurokawa Y; Eguchi H; Doki Y
    Esophagus; 2024 Jul; 21(3):319-327. PubMed ID: 38717686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study.
    Kashimura S; Sato M; Inagaki T; Kin M; Manabe R; Kusumoto S; Horiike A; Tsunoda T; Kogo M
    Thorac Cancer; 2024 Oct; 15(28):2049-2060. PubMed ID: 39193939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
    Booka E; Kikuchi H; Haneda R; Soneda W; Kawata S; Murakami T; Matsumoto T; Hiramatsu Y; Takeuchi H
    Anticancer Res; 2022 Jun; 42(6):2977-2987. PubMed ID: 35641297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
    Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
    Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
    J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer.
    Gou M; Qu T; Wang Z; Yan H; Si Y; Zhang Y; Dai G
    J Immunol Res; 2021; 2021():2549295. PubMed ID: 34993252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
    Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
    Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 36. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Neutrophil-Lymphocyte Ratio as a Prognostic Indicator in Patients Treated with Nivolumab for Gastric Cancer].
    Fujita K; Haruki N; Kurehara H; Ochi N; Yamakawa Y; Harata S; Tsumoto C; Tsuji T; Ito T; Izumi A; Usui R; Shinoda N
    Gan To Kagaku Ryoho; 2020 Jun; 47(6):923-926. PubMed ID: 32541169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 39. Baseline Neutrophil-to-Lymphocyte Ratio and Glasgow Prognostic Score are Associated with Clinical Outcome in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
    Chikuie N; Hamamoto T; Ueda T; Taruya T; Kono T; Furuie H; Ishino T; Takeno S
    Acta Med Okayama; 2021 Jun; 75(3):335-343. PubMed ID: 34176937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.